Recipharm Pharmaservices Profile
Key Indicators
- Authorised Capital ₹ 610.00 Cr
as on 15-05-2024
- Paid Up Capital ₹ 418.70 Cr
as on 15-05-2024
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -8.38%
(FY 2022)
- Profit 82.93%
(FY 2022)
- Ebitda -11.04%
(FY 2022)
- Net Worth 9.81%
(FY 2022)
- Total Assets 10.88%
(FY 2022)
About Recipharm Pharmaservices
The Corporate was formerly known as Dagny Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 610.00 Cr and a paid-up capital of Rs 418.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Recipharm Pharmaservices Private Limited India is Suresh Ganachari as COMPANY SECRETARY. Suresh Ganachari, Ina Quinn, and Srinivas Davuluri serve as directors at the Company.
- CIN/LLPIN
U24230KA2015PTC084997
- Company No.
084997
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore Rural, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Recipharm Pharmaservices?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srinivas Davuluri | Managing Director | 29-Dec-2023 | Current |
Suresh Ganachari  | Company Secretary | 15-Feb-2017 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Suresh Ganachari | Whole-Time Director and Company Secretary | 28-Nov-2022 | Current |
| Ina Quinn | Director | 05-Jan-2023 | Current |
Financial Performance and Corporate Structure Insights of Recipharm Pharmaservices.
Recipharm Pharmaservices Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.38% decrease. The company also saw a substantial improvement in profitability, with a 82.93% increase in profit. The company's net worth moved up by a moderate rise of 9.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Recipharm Pharmaservices?
In 2022, Recipharm Pharmaservices had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Recipharm Lifesciences India Private LimitedActive 7 years 10 monthsSuresh Ganachari is a mutual person
Recipharm Holding India Private LimitedActive 8 years 9 monthsSuresh Ganachari and Suresh Ganachari are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Recipharm Pharmaservices?
Recipharm Pharmaservices has a workforce of 1077 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Recipharm Pharmaservices, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Recipharm Pharmaservices's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
